Loading...
Derniers manuscrits de l'équipe
-
-
Isabelle L Ray-Coquard, Aude-Marie Savoye, Camille Schiffler, Marie-Ange Mouret-Reynier, Olfa Derbel, et al.. Neoadjuvant and adjuvant pembrolizumab in advanced high-grade serous carcinoma: the randomized phase II NeoPembrOV clinical trial. Nature Communications, 2024, 15 (1), pp.5931. ⟨10.1038/s41467-024-46999-x⟩. ⟨hal-04765682⟩
-
-
-
Gilles Freyer, Anne Floquet, Olivier Trédan, Aurore Carrot, Carole Langlois-Jacques, et al.. Bevacizumab, olaparib, and durvalumab in patients with relapsed ovarian cancer: a phase II clinical trial from the GINECO group. Nature Communications, 2024, 15 (1), pp.1985. ⟨10.1038/s41467-024-45974-w⟩. ⟨hal-04549309⟩
-
Aina Bellver-Sanchis, Pedro A Ávila-López, Iva Tic, David Valle-García, Marta Ribalta-Vilella, et al.. Neuroprotective effects of G9a inhibition through modulation of peroxisome-proliferator activator receptor gamma-dependent pathways by miR-128. Neural Regeneration Research, 2024, 19, pp.2532 - 2542. ⟨10.4103/1673-5374.393102⟩. ⟨hal-04947683⟩
Chiffres clés
80
Publications with fulltext